Supplementary information on cannabis-based products for medicinal use
22nd November 2018
Supplementary information has been published to clarify the status of the recent NHS England guidance to clinicians that was published on 31 October 2018 (see our news item) and provide clarification surrounding synthetic cannabinoids for medicinal use, e.g. dronabinol and nabilone.
Recent news
- RPS Wales Palliative and End of Life Care Policy
- NICE guidelines for COPD updated
- AWMSG approves tiotropium
- Palliative Care Formulary migration to MedicinesComplete - January 2019
- Supplementary information on cannabis-based products for medicinal use
- Report on action taken on ambulatory syringe drivers
- NICE consultation on cannabis-based products for medicinal use
- Guidance and information on prescribing and supply of cannabis-based products for medicinal use
- Instanyl (fentanyl) multidose nasal sprays discontinued
- Gabapentin and pregabalin to be controlled as class C drugs
News archive
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000